![Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial | Critical Care | Full Text Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial | Critical Care | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13054-022-04205-8/MediaObjects/13054_2022_4205_Fig1_HTML.png)
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial | Critical Care | Full Text
![Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial | Critical Care | Full Text Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial | Critical Care | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13054-022-04205-8/MediaObjects/13054_2022_4205_Fig2_HTML.png)
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial | Critical Care | Full Text
![Nyhende, Kor blei dei av | Ho gav heile landet innblikk i livet som ung mor med ein gut med downs syndrom – dette gjer Gunn-Britt (31) i dag Nyhende, Kor blei dei av | Ho gav heile landet innblikk i livet som ung mor med ein gut med downs syndrom – dette gjer Gunn-Britt (31) i dag](https://g.acdn.no/obscura/API/dynamic/r1/ece5/tr_1000_2000_s_f/0000/kvin/2021/1/27/13/142444214_262780818567479_9032285955411671013_n.jpg?chk=EBF19E)